Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Read
Blockbuster SAR-CoV2 Disrupters Pre-ICU / Admitted ICU Patient Treatments & COVID-19 T-Cell Vaccine Horizon
Article By:
James Gornick
Wednesday, July 22, 2020 5:50 AM EDT
In recent months, there has been a flurry of activity within the clinical trial sector. When all trial types are considered, there are over 400 studies exploring approaches to diagnosing, treating, or preventing COVID-19.
Athersys Inc. Announces Positive Phase 2 Stroke Results
Article By:
Terry Chrisomalis
Thursday, February 18, 2016 12:50 AM EDT
Athersys up 21% in after-hours trade after announcing positive phase 2 stroke trial results.
In this article: ATHX
Athersys Fails Stroke Trial In Mid-Stage Study
Article By:
Terry Chrisomalis
Friday, April 17, 2015 12:02 PM EDT
Shares of Athersys are down almost 50% on the news of failing a phase 2 trial for stroke with the company using its multistem cell therapy
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Article By:
The Life Sciences Report
Friday, January 23, 2015 5:48 PM EDT
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. Edward Stopke of Sagient Research unveils his list of companies with catalytic moments in the making.
In this article: PSTV, VCEL, ATHX, BLUE, CUR, KITE, NVS, AMGN, JUNO, RNN, MRK, ESALF, RPTP, CLDX, SRPT, PTCT, GILD, RMTI